Evolution at 6 months of individual and haemodynamic parameters in patients treated with initiation or escalation of immunosuppressive therapy alone
| Patient | Sex | Age years | Extrinsic pulmonary artery compression | Increased 18F-FDG uptake in PET scan | Radiological stage | FVC % | WHO/NYHA functional class | 6MWD m | mPAP mmHg | Cardiac index L·min−1·m−2 | PVR Wood units | Immunosuppressive therapy | |||||
| T0 | T6 | T0 | T6 | T0 | T6 | T0 | T6 | T0 | T6 | ||||||||
| 1 | Male | 66 | Yes (lymph nodes) | Yes | 1 | 96 | III | II | 490 | 540 | 38 | 29 | 3.1 | 3.7 | 3.2 | 1.9 | Methotrexate |
| 2 | Female | 40 | Yes (lymph nodes) | Yes | 1 | 100 | III | II | ND | 420 | 51 | 29 | 2.1 | 2.2 | 11.7 | 4.2 | Prednisone 60 mg·day−1 |
| 3 | Female | 55 | Yes (fibrosing mediastinitis) | Yes | 1 | 42 | III | II | 190 | 195 | 46 | 30 | 3.3 | 2.6 | 7.4 | 6.5 | Prednisone 60 mg·day−1 |
| 4 | Male | 67 | Yes (fibrosing mediastinitis) | No | 4 | 57 | II | II | 550 | 530 | 42 | 46 | 2.8 | 1.9 | 6.3 | 10.6 | Prednisone 30 mg·day−1 |
| 5 | Female | 58 | Yes (fibrosing mediastinitis) | ND | 4 | 40 | III | III | 390 | 367 | 48 | 39 | 2.8 | 2.9 | 7.3 | 8.4 | Prednisone 30 mg·day−1 |
| 6 | Female | 45 | No | ND | 4 | 77 | III | III | 449 | 462 | 39 | 28 | 2.8 | 2.9 | 6.5 | 4.8 | Prednisone 60 mg·day−1 |
| 7 | Male | 41 | No | ND | 4 | 52 | II | IV | 525 | 270 | 39 | 45 | 2.3 | ND | 7.7 | ND | Prednisone 60 mg·day−1 |
| 8 | Male | 64 | No | ND | 2 | 63 | III | III | 388 | 377 | 42 | 30 | 4.3 | 2.6 | 4.9 | 4.7 | Prednisone 60 mg·day−1 |
| 9 | Female | 68 | No | ND | 4 | 65 | III | III | 242 | ND | 44 | 25 | 3.3 | 4.0 | 7.0 | 3.6 | Azathioprine 100 mg·day−1 |
| 10 | Female | 65 | No | ND | 4 | 108 | II | III | 410 | 310 | 48 | 38 | 4.1 | 3.3 | 6.5 | 6.6 | Prednisone 40 mg·day−1 |
| 11 | Male | 79 | No | ND | 4 | 48 | III | III | 509 | ND | 56 | 46 | 2.3 | 2.4 | 9.3 | 9.5 | Prednisone 60 mg·day−1 |
18F-FDG: 18F-2-fluoro-2-deoxy-d-glucose; PET: positron emission tomography; FVC: forced vital capacity; WHO: World Health Organization; NYHA: New York Heart Association; 6MWD: 6-min walk distance; mPAP: mean pulmonary artery pressure; PVR: pulmonary vascular resistance; T0: baseline visit; T6: 6-month visit; ND: no data available.